Journal article · 2023 · Open access

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data

Hong Ki Min, Hyeongsu Kim, Ho Jin Jeong, Hae‐Rim Kim, Hae-Rim Kim, Jong Heon Park, Kun-Sei Lee, Soon‐Ae Shin, Jong Heon Park

Epidemiology and Health, 45, e2023045 · Published 15 April 2023 · DOI 10.4178/epih.e2023045

Open PDFView at the publisherCite this paper

In brief

“Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data” is a 2023 journal article by Hong Ki Min and 8 co-authors, published in Epidemiology and Health. OpenAlex counts 27 citations as of 19 November 2026, which puts it in the top 5% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Epidemiology and Health.

Citations
27
Most cited in
2025 (13)
Field-weighted impact
4.50
References
40
Authors
9

Abstract

OBJECTIVES: This study investigated whether Janus kinase inhibitors (JAKis) raise the risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and cancer in patients with rheumatoid arthritis (RA). METHODS: We conducted a real-world retrospective observational study using data obtained from the Korean National Health Insurance Service database. Two data sets were analyzed: tumor necrosis factor inhibitor (TNFi)/JAKi-naive RA patients (set 1) and all RA patients who used TNFis or JAKis (set 2). The incidence rate ratios (IRRs) and hazard ratios (HRs) for acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), VTE, arterial thromboembolism (ATE), cancer, and all-cause mortality were compared between the JAKi and TNFi groups. RESULTS: Set 1 included 1,596 RA patients (JAKi group: 645; TNFi group: 951), and set 2 included 11,765 RA patients (JAKi group: 2,498; TNFi group: 9,267). No adverse events (AEs) showed significantly higher IRRs in the JAKi groups than in the TNFi groups of sets 1 and 2. The HRs for MACE in the JAKi groups of sets 1 and 2 were 0.59 (95% confidence [CI], 0.35 to 0.99) and 0.80 (95% CI, 0.67 to 0.97), respectively. The JAKi group of set 2 showed a significantly higher risk of all-cause mortality (HR, 1.71; 95% CI, 1.32 to 2.20), but the other AEs did not demonstrate increased risks in the JAKi groups. CONCLUSIONS: In this study, JAKis did not increase the risk of AMI, stroke, CV-related mortality, MACE, VTE, ATE, or cancer in Korean RA patients relative to TNFis.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Min, H. K., Kim, H., Jeong, H. J., Kim, H., Kim, H.-R., Park, J. H., Lee, K.-S., Shin, S., & Park, J. H. (2023). Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiology and Health, 45, e2023045. https://doi.org/10.4178/epih.e2023045

MLA 9

Min, Hong Ki, et al. “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.” Epidemiology and Health, vol. 45, 2023, p. e2023045. https://doi.org/10.4178/epih.e2023045.

Chicago

Min, Hong Ki, Hyeongsu Kim, Ho Jin Jeong, Hae‐Rim Kim, Hae-Rim Kim, Jong Heon Park, Kun-Sei Lee, Soon‐Ae Shin, and Jong Heon Park. 2023. “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.” Epidemiology and Health 45: e2023045. https://doi.org/10.4178/epih.e2023045.

Harvard

Min, H. K. et al. (2023) ‘Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data’, Epidemiology and Health, 45, p. e2023045. doi:10.4178/epih.e2023045.

IEEE

H. K. Min et al., “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data,” Epidemiology and Health, vol. 45, p. e2023045, 2023, doi: 10.4178/epih.e2023045.

BibTeX

@article{min2023risk,
  title     = {{Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data}},
  author    = {Min, Hong Ki and Kim, Hyeongsu and Jeong, Ho Jin and Kim, Hae‐Rim and Kim, Hae-Rim and Park, Jong Heon and Lee, Kun-Sei and Shin, Soon‐Ae and Park, Jong Heon},
  journal   = {Epidemiology and Health},
  year      = {2023},
  volume    = {45},
  pages     = {e2023045},
  doi       = {10.4178/epih.e2023045},
  url       = {https://doi.org/10.4178/epih.e2023045}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202333
202444
20251313
202677

Its field-weighted citation impact is 4.50: it has been cited 4.50 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tumor necrosis factor inhibitors
  • cardiovascular disease
  • venous thromboembolism
  • arterial thromboembolism
  • cancer risk
  • mortality

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Min, H. K., Kim, H., Jeong, H. J., Kim, H., Kim, H.-R., Park, J. H., Lee, K.-S., Shin, S., & Park, J. H. (2023). Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiology and Health, 45, e2023045. https://doi.org/10.4178/epih.e2023045

How many times has this paper been cited?

27 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Epidemiology and Health: sign in and open the PDF from this page.

Who wrote this paper?

Hong Ki Min, Hyeongsu Kim, Ho Jin Jeong, Hae‐Rim Kim, Hae-Rim Kim, Jong Heon Park, Kun-Sei Lee, Soon‐Ae Shin, Jong Heon Park.

What is the DOI of this paper?

10.4178/epih.e2023045, permanently at https://doi.org/10.4178/epih.e2023045. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.